<DOC>
	<DOCNO>NCT00362102</DOCNO>
	<brief_summary>To evaluate response rate cetuximab plus irinotecan combination therapy subject EGFR-detectable metastatic colorectal carcinoma document progressive disease irinotecan-based chemotherapy fail ( progressive disease intolerance ) previous oxaliplatin-based fluoropyrimidine-based chemotherapy .</brief_summary>
	<brief_title>A Phase II Study Cetuximab Plus Irinotecan Patients With EGFR-detectable Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The subject must surgically unresectable metastatic colorectal carcinoma . The subject receive failed Ilinotecan , oxaliplatin fluoropyrimidinebased chemotherapy ECOG PS 02 Subjects symptomatic cerebral metastasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>EGFR-detectable metastatic colorectal carcinoma document progressive disease irinotecan-based chemotherapy failure</keyword>
</DOC>